CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.

The program will include presentations by Cerus’ executive team covering the Company’s business strategy and long term revenue growth drivers. Cerus will also provide a detailed update on its development programs including the red blood cell system as well as pathogen-reduced cryoprecipitate. In addition, guest speakers will provide clinical perspectives on the blood component transfusion industry.

Registration begins at 9:00 a.m. ET with presentations starting at 9:30 a.m. ET and concluding at approximately 12:00 noon ET.

Institutional investors and analysts are invited to attend in person and are encouraged to register in advance by emailing Investor Relations at [email protected].

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181002005350/en/

Cerus Corporation

Tim Lee, 925-288-6137

Investor Relations Director

Source: Cerus Corporation

Press Releases